| Bruce Albrecht, OTRL/L | |
|
3219 Central Ave, Kearney, NE 68847-2949 | |
| (308) 865-2727 | |
| (308) 865-2912 |
| Full Name | Bruce Albrecht |
|---|---|
| Gender | Male |
| Speciality | Occupational Therapy |
| Experience | 29 Years |
| Location | 3219 Central Ave, Kearney, Nebraska |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083005946 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | 454 (Nebraska) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Central Nebraska Rehabilitation Services Llc | 0749258994 | 81 |
News Archive
A team of researchers at the California Institute of Technology (Caltech) has devised a new method for making complex molecules. The reaction they have come up with should enable chemists to synthesize new varieties of a whole subclass of organic compounds called nitrogen-containing heterocycles, thus opening up new avenues for the development of novel pharmaceuticals and natural products ranging from chemotherapeutic compounds to bioactive plant materials such as morphine.
Working with cells taken from children with a very rare but ferocious form of brain cancer, Johns Hopkins Kimmel Cancer Center scientists have identified a genetic pathway that acts as a master regulator of thousands of other genes and may spur cancer cell growth and resistance to anticancer treatment.
A new clinical Standard Reference Material (SRM) from the National Institute of Standards and Technology (NIST) will help health care professionals more accurately diagnose and treat cytomegalovirus (CMV), a common pathogen that is particularly dangerous for infants and persons with weakened immune systems.
Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.
Sinovac Biotech announced today that it has completed construction of the H1N1 virus seed bank necessary to produce a virus antigen.
› Verified 9 days ago
| Provider Name | Central Nebraska Rehabilitation Services Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1184627911 PECOS PAC ID: 0749258994 Enrollment ID: O20120303000002 |
News Archive
A team of researchers at the California Institute of Technology (Caltech) has devised a new method for making complex molecules. The reaction they have come up with should enable chemists to synthesize new varieties of a whole subclass of organic compounds called nitrogen-containing heterocycles, thus opening up new avenues for the development of novel pharmaceuticals and natural products ranging from chemotherapeutic compounds to bioactive plant materials such as morphine.
Working with cells taken from children with a very rare but ferocious form of brain cancer, Johns Hopkins Kimmel Cancer Center scientists have identified a genetic pathway that acts as a master regulator of thousands of other genes and may spur cancer cell growth and resistance to anticancer treatment.
A new clinical Standard Reference Material (SRM) from the National Institute of Standards and Technology (NIST) will help health care professionals more accurately diagnose and treat cytomegalovirus (CMV), a common pathogen that is particularly dangerous for infants and persons with weakened immune systems.
Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.
Sinovac Biotech announced today that it has completed construction of the H1N1 virus seed bank necessary to produce a virus antigen.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Bruce Albrecht, OTRL/L Po Box 5285, Grand Island, NE 68802-5285 Ph: (308) 382-0344 | Bruce Albrecht, OTRL/L 3219 Central Ave, Kearney, NE 68847-2949 Ph: (308) 865-2727 |
News Archive
A team of researchers at the California Institute of Technology (Caltech) has devised a new method for making complex molecules. The reaction they have come up with should enable chemists to synthesize new varieties of a whole subclass of organic compounds called nitrogen-containing heterocycles, thus opening up new avenues for the development of novel pharmaceuticals and natural products ranging from chemotherapeutic compounds to bioactive plant materials such as morphine.
Working with cells taken from children with a very rare but ferocious form of brain cancer, Johns Hopkins Kimmel Cancer Center scientists have identified a genetic pathway that acts as a master regulator of thousands of other genes and may spur cancer cell growth and resistance to anticancer treatment.
A new clinical Standard Reference Material (SRM) from the National Institute of Standards and Technology (NIST) will help health care professionals more accurately diagnose and treat cytomegalovirus (CMV), a common pathogen that is particularly dangerous for infants and persons with weakened immune systems.
Rigel Pharmaceuticals, Inc. today announced that it has earned $25 million from AstraZeneca for the fulfillment of two major milestones in the agreement the two companies have regarding the clinical development of fostamatinib (R788), a novel oral syk inhibitor. The first milestone is for initiation of the phase 3 clinical program with fostamatinib in patients with rheumatoid arthritis (RA) that was announced by AstraZeneca earlier today.
Sinovac Biotech announced today that it has completed construction of the H1N1 virus seed bank necessary to produce a virus antigen.
› Verified 9 days ago
Rogene Rasmussen, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 211 W 33rd St Ste A, Kearney, NE 68845 Phone: 308-236-5884 Fax: 308-236-9621 | |
Luke Minturn, OTR/L Occupational Therapist Medicare: Accepting Medicare Assignments Practice Location: 620 E 25th St Ste 7, Kearney, NE 68847 Phone: 308-455-1781 | |
Brendon Timothy Menke, OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 2707 2nd Ave Ste B, Kearney, NE 68847 Phone: 308-234-1278 Fax: 308-234-1279 | |
Sara Marie O'neill, OTD, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3811 29th Ave Ste 2, Kearney, NE 68845 Phone: 308-233-5060 Fax: 308-233-5062 | |
Miss Lauren Kay Erickson, OTD OTR/L Occupational Therapist Medicare: Medicare Enrolled Practice Location: 2810 W 35th St, Ste 2, Kearney, NE 68845 Phone: 308-237-7388 Fax: 308-237-7394 | |
Amy Marie Haskett, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1511 5th Ave, Kearney, NE 68845 Phone: 308-698-5622 |